Pfizer Update and Customer Letter Regarding COVID-19 (March 2020)


CCPAPP and Pfizer would like to provide our members with an update as it relates to Pfizer's response to the COVID-19 (Coronavirus) pandemic. Effective March 26, 2020 Pfizer has implemented a temporary payment terms extension for Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and Trumenba® (Meningococcal Group B Vaccine). Please note: CCPAPP's partnership with Pfizer is for discounted pricing on the Trumenba vaccine. CCPAPP does not have an agreement in place with Pfizer for Prevnar 13.

All open invoices dated January 1, 2020 or later for Pfizer vaccines purchased directly through Pfizer will automatically have an additional 30 days added to their existing payment terms. No action is required from our members and no new invoices will be issued; members may simply make note of the additional 30 days on their current invoices.

Additionally, all NEW orders placed directly through Pfizer between March 26, 2020 and May 31, 2020 will have extended payment terms of 105 days with the 2% prompt pay discount.

Please review Pfizer's Customer Letter Dated March 26 2020 regarding this temporary extension as well as further details regarding Pfizer's plan to battle Covid-19. Please contact your Pfizer Vaccines Territory Manager or call Pfizer Customer Service at 1.800.666.7248 with any questions. CCPAPP-Pfizer pricing for Trumenba can be found on the Pricing Page of our website. Members will need their username and password to access the information. For assistance, or further questions regarding this update please contact CCPAPP at or by phone at 312.227.7444.

We wish all of our members the best as they work passionately to care for their patients during this challenging time!



« Back